Headlands Technologies’s Ascendis Pharma A/S ASND Stock Holding History

Headlands Technologies’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-898	Closed	-$205K	–	724
2026 Q1	$205K	Sell	898 -10,666	-92%	-$2.39M	0.02%	592
2025 Q4	$2.47M	Buy	+11,564	New	+$2.39M	0.21%	105
2025 Q3	–	Sell	-1,196	Closed	-$206K	–	647
2025 Q2	$206K	Buy	+1,196	New	+$195K	0.02%	458
2024 Q4	–	Sell	-699	Closed	-$104K	–	1194
2024 Q3	$104K	Sell	699 -5,639	-89%	-$762K	0.01%	660
2024 Q2	$864K	Buy	+6,338	New	+$862K	0.09%	189
2024 Q1	–	Sell	-121	Closed	-$15.2K	–	1242
2023 Q4	$15.2K	Buy	+121	New	+$12.1K	﹤0.01%	708

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Headlands Technologies's ASND Position: Q2 2026 in Review

Headlands Technologies sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 898 shares — an estimated $205K sold.

Headlands Technologies first reported a position in ASND in Q4 2023 and held it in 6 quarters. The position peaked at $2.47M in Q4 2025. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Headlands Technologies reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Headlands Technologies sold 898 Ascendis Pharma A/S shares in Q2 2026, an estimated $205K.
Headlands Technologies first reported a position in Ascendis Pharma A/S in Q4 2023 and held it in 6 quarters.
Headlands Technologies's Ascendis Pharma A/S position peaked at $2.47M in Q4 2025.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.